Evidence map›Paper›PMID 32578281›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2020

Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti-Paratyphoid Fever Vaccines.

Debashis Dhara, Scott M Baliban, Chang-Xin Huo, Zahra Rashidijahanabad, Khandra T Sears, Setare Tahmasebi Nick, Anup Kumar Misra, Sharon M Tennant, Xuefei Huang

Open access · greenAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Frontiers in immunology · 2023
    Article
  8. Article
  9. Review
  10. Virus-like Particle Display ofACS infectious diseases · 2022
    Article
  11. Paratyphoid Fever A: Infection and Prevention.Frontiers in microbiology · 2022
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Debashis DharaDivision of Molecular Medicine, Bose Institute, P-1/12, C.I.T. Scheme VII M, Kolkata, 700054, India.
Scott M BalibanCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Chang-Xin HuoDepartment of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Zahra RashidijahanabadDepartment of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Khandra T SearsCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Setare Tahmasebi NickDepartment of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Anup Kumar MisraDivision of Molecular Medicine, Bose Institute, P-1/12, C.I.T. Scheme VII M, Kolkata, 700054, India.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Xuefei HuangDepartment of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.ORCID http://orcid.org/0000-0002-6468-5526
Michigan State University · USUniversity of Maryland, Baltimore · USBose Institute · IN

Funding

Miriam/Brown/Tufts Fogarty AIDS International Training and Research ProgramD43TW000237 · FIC · MIRIAM HOSPITAL · PI CU-UVIN, SUSAN · 1993 to 2014
$10.6M
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccinesR01AI146210 · NIAID · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2019 to 2023
$1.5M
NIAID NIH HHS R01 AI146210NIAID NIH HHS T32 AI007524
6 · The paper itself

Abstract

With the emergence of multidrug resistant Salmonella strains, the development of anti-Salmonella vaccines is an important task. Currently there are no approved vaccines against Salmonella Paratyphi A, the leading cause of paratyphoid fever. To fill this gap, oligosaccharides corresponding to the O-polysaccharide repeating units from the surface of Salmonella Paratyphi A have been synthesized through convergent stereoselective glycosylations. The synthetic glycan antigen was conjugated with a powerful immunogenic carrier system, the bacteriophage Qβ. The resulting construct was able to elicit strong and long-lasting anti-glycan IgG antibody responses, which were highly selective toward Salmonella Paratyphi A associated glycans. The availability of well-defined glycan antigen enabled the determination that one repeating unit of the polysaccharide is sufficient to induce protective antibodies, and the paratose residue and/or the O-acetyl modifications on the backbone are important for recognition by antibodies elicited by a Qβ-tetrasaccharide conjugate. Immune sera provided excellent protection to mice from lethal challenge with Salmonella Paratyphi A, highlighting the potential of the synthetic glycan-based vaccine.

Indexed as

OligosaccharidesParatyphoid FeverSalmonella paratyphi ATyphoid-Paratyphoid VaccinesAnimalsAntibodies, BacterialAntigens, BacterialMiceVaccines, SyntheticAntibodies, BacterialAntigens, BacterialOligosaccharidesTyphoid-Paratyphoid VaccinesVaccines, Syntheticbacteriabiochemistryglycosylationsalmonella paratyphi Asynthesisvaccine

Identifiers

PMID32578281
PMCPMC7722144
OpenAlexW3037903771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.